
Wissam Zam¹, Cristina Quispe², Javad Sharifi-Rad³,*, Maria Dolores López⁴, Mauricio Schoebitz⁵, Miquel Martorell⁶, Farukh Sharopov⁷,*, Patrick Valere Tsouh Fokou⁸, Abhay Prakash Mishra⁹, Deepak Chandran¹⁰, Manoj Kumar¹¹, Jen-Tsung Chen¹²,*, Raffaele Pezzani¹³,¹⁴,*

¹Department of Analytical and Food Chemistry, Faculty of Pharmacy, Al-Andalus University for Medical Sciences, 35XQ+C2F Tartous, Syria
²Facultad de Ciencias de la Salud, Universidad Arturo Prat, Avda. Arturo Prat 2120, 1110939 Iquique, Chile
³Facultad de Medicina, Universidad del Azuay, 14-008 Cuenca, Ecuador
⁴Department of Plant Production, Faculty of Agronomy, Universidad de Concepción, Avenida Vicente Mendez, 595, 3812120 Chillán, Chile
⁵Departamento de Suelos y Recursos Naturales, Facultad de Agronomía, Universidad de Concepción, 4070386 Concepción, Chile
⁶Department of Nutrition and Dietetics, Faculty of Pharmacy, and Centre for Healthy Living, University of Concepción, 4070386 Concepción, Chile
⁷Research Institution “Chinese-Tajik Innovation Center for Natural Products” of the National Academy of Sciences of Tajikistan, Ayni str. 299/2, 734063 Dushanbe, Tajikistan
⁸Faculty of Science, University of Bamenda, 39 Bamenda-Bambili, Cameroon
⁹Department of Pharmacology, University of Free State, 9300 Bloemfontein, South Africa
¹⁰Department of Veterinary Sciences and Animal Husbandry, Amrita School of Agricultural Sciences, Amrita Vishwa Vidyapeetham University, Coimbatore, 642109 Tamil Nadu, India
¹¹Chemical and Biochemical Processing Division, ICAR – Central Institute for Research on Cotton Technology, 400019 Mumbai, India
¹²Department of Life Sciences, National University of Kaohsiung, 811 Kaohsiung, Taiwan
¹³Phytotherapy Lab (PhT-Lab), Endocrinology Unit, Department of Medicine (DIMED), University of Padova, via Ospedale 105, 35128 Padova, Italy
¹⁴AIROB, Associazione Italiana per la Ricerca Oncologica di Base, 35046 Padova, Italy
*Correspondence: javad.sharifirad@gmail.com (Javad Sharifi-Rad); shfarukh@mail.ru (Farukh Sharopov); jentsung@nuk.edu.tw (Jen-Tsung Chen); raffaele.pezzani@unipd.it (Raffaele Pezzani)

Academic Editor: Gustavo Caetano-Anollés
Submitted: 4 August 2022  Accepted: 24 November 2022  Published: 7 December 2022

The authors would like to make a correction to the article [1]. The authors clarify that the reference [2] in the Fig. 5 caption is not cited in this review article in error. We apologise to readers for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The references in the article have also been updated.

References
An Updated Review on The Properties of Melissa officinalis L.: Not Exclusively Anti-anxiety

Wissam Zam1, Cristina Quispe2, Javad Sharifi-Rad3,*, Maria Dolores López4, Mauricio Schoebitz3, Miquel Martorell6, Farukh Sharopov7,*, Patrick Valere Tsou Fokou8, Abhay Prakash Mishra9, Deepak Chandran10, Manoj Kumar11, Jen-Tsung Chen12,*, Raffaele Pezzani13,14,*

1Department of Analytical and Food Chemistry, Faculty of Pharmacy, Al-Andalus University for Medical Sciences, 35XQ+C2F Tartous, Syria
2Facultad de Ciencias de la Salud, Universidad Arturo Prat, Avda. Arturo Prat 2120, 1110939 Iquique, Chile
3Facultad de Medicina, Universidad del Azuay, 14-008 Cuenca, Ecuador
4Department of Plant Production, Faculty of Agronomy, Universidad de Concepción, Avenida Vicente Mendez, 595, 3812120 Chillán, Chile
5Departamento de Suelos y Recursos Naturales, Facultad de Agronomía, Universidad de Concepción, 4070386 Concepción, Chile
6Department of Nutrition and Dietetics, Faculty of Pharmacy, and Centre for Healthy Living, University of Concepción, 4070386 Concepción, Chile
7Research Institution “Chinese-Tajik Innovation Center for Natural Products” of the National Academy of Sciences of Tajikistan, Ayni str. 299/2, 734063 Dushanbe, Tajikistan
8Faculty of Science, University of Bamenda, 39 Bamenda-Bambili, Cameroon
9Department of Pharmacology, University of Free State, 9300 Bloemfontein, South Africa
10Department of Veterinary Sciences and Animal Husbandry, Amrita School of Agricultural Sciences, Amrita Vishwa Vidyapeetham University, Coimbatore, 642109 Tamil Nadu, India
11Chemical and Biochemical Processing Division, ICAR – Central Institute for Research on Cotton Technology, 400019 Mumbai, India
12Department of Life Sciences, National University of Kaohsiung, 811 Kaohsiung, Taiwan
13Phytotherapy Lab (PhT-Lab), Endocrinology Unit, Department of Medicine (DIMED), University of Padova, via Ospedale 105, 35128 Padova, Italy
14AIOB, Associazione Italiana per la Ricerca Oncologica di Base, 35046 Padova, Italy
*Correspondence: javad.sharifrad@gmail.com (Javad Sharifi-Rad); jentsung@nuk.edu.tw (Jen-Tsung Chen); raffaele.pezzani@unipd.it (Raffaele Pezzani); shfarukh@mail.ru (Farukh Sharopov)

Academic Editor: Gustavo Caetano-Anollés
Submitted: 2 February 2022 Revised: 30 March 2022 Accepted: 11 April 2022 Published: 7 June 2022

Abstract

Melissa officinalis L. is a plant of the Lamiaceae family known in numerous countries for its medicinal activities. This plant has been used since ancient times to treat different disorders, including gastrointestinal, cardiovascular, neurological, psychological conditions. M. officinalis contains several phytochemicals such as phenolic acids, flavonoids, terpenoids, and many others at the basis of its pharmacological activities. Indeed, the plant can have antioxidant, anti-inflammatory, antispasmodic, antimicrobial, neuroprotective, nephroprotective, antinociceptive effects. Given its consolidated use, M. officinalis has also been experimented with clinical settings, demonstrating interesting properties against different human diseases, such as anxiety, sleeping difficulties, palpitation, hypertension, depression, dementia, infantile colic, bruxism, metabolic problems, Alzheimer’s disease, and sexual disorders. As for any natural compound, drug, or plant extract, also M. officinalis can have adverse effects, even though the reported events are very rare and the plant can be considered substantially safe. This review has been prepared with a specific research strategy, interrogating different databases with the keyword M. officinalis. Moreover, this work analyzes the properties of this plant updating currently available literature, with a special emphasis on human studies.

Keywords: Melissa officinalis L.; lemon balm; phytotherapy; phytochemicals; health properties; clinical trials

1. Introduction

In today’s world, the prevalence of anxiety disorders has skyrocketed. Anxiolytics can be used to treat these illnesses, although they can have some negative side effects despite their effectiveness. Because of the lack of understanding about drug interactions and possible harmful effects, traditional medicine poses a serious risk to public health. Plants’ clinical efficacy must be evaluated in research investigations. Melissa officinalis L., popularly known as lemon balm, is utilized in traditional medicine for its effects on CNS processes such as sedation and memory improvement and additionally possess various health benefits if consumed in optimum concentration but unfortunately, no comprehensive compilation has been done so far [1]. The majority of beneficial effects of the Therefore, it is important to present complete information of Melissa officinalis L. are due to volatile oils, triterpenes, and pheno- nolic compounds.

An increasing body of evidence suggests that this plant may have therapeutic potential in the management of dis-
orders such as diabetes and Alzheimer’s disease. It also contains antioxidant, antibacterial, and anti-inflammatory properties [2,3]. The low toxicity and lack of side effects of this plant have been proven in several investigations utilizing different experimental models [4]. But if the plant extracts are not used optimally, they may exert toxicity both in cell and animal models. In the clinical trials, the effect of *M. officinalis* extracts has been proved evaluated on a variety of diseases, mainly related to neurological disorders, i.e., anxiety and sleeping difficulties, but also metabolic problems and infantile colic and shown to have positive effects. The present review was aimed to compile information on botany and phytochemistry, traditional medicinal, and ethnopharmacological uses of *M. officinalis*, and also various clinical aspects and biomedical properties of this well-known plant are discussed.

This review has been prepared through an interrogation of different databases, such as Chrocarne library, Embase-Elsevier, Google Scholar, Ovid, PubMed, Science Direct, SciFinder, Scopus, Web of Science. Both articles, papers, and books have been considered, while the search strategy was based on the keyword *Melissa officinalis*, in addition to its English translation or common names as “common balm”, “honey balm”, “lemon balm”, “melissa balm”, “sweet balm”.

2. Botany of *Melissa officinalis*

*Melissa officinalis* can be taxonomically classified as follows: Kingdom: Plantae; Division: Tracheophyta; Subdivision: Spermatophyta; Class: Magnoliopsida; Superorder: Asterales; Order: Lamiales; Family: Lamiaceae; Genus: Melissa; Species: *Melissa officinalis* L. [5].

From a botanical point of view, *Melissa officinalis* L. (Greek word “Melissa”—honeybee) is the only acceptable name for the plant and possesses different accepted varieties, i.e., *M. officinalis* var. *altissima* (Sm.) K.Koch, *M. officinalis* var. *cordifolia* (Pers.) K.Koch, *M. officinalis* var. *foliosa* Briq., *M. officinalis* var. *graveolens* (Host) Nyman, *M. officinalis* var. *hirsuta* K. Koch, *M. officinalis* var. *romana* (Mill.) Woody. and *M. officinalis* var. *villosa* Benth [6,7]. *M. officinalis* L. is also known as lemon balm, bee balm, sweet balm, common balm, honey balm [5,6].

There is also an infraspecific taxon of the species *M. officinalis* which are naturally exploited in our wild flora: *M. officinalis* ssp. *altissima* (Sm.) Arcang., *M. officinalis* ssp. *officinalis*, *M. officinalis* subsp. *inodora* Bornm [8,9]. *M. officinalis* shows economic significance because there is an increase in growth terrain and novel varieties exploration [9].

A haploid base number of *M. officinalis* of *x* = 16 chromosomes is likely, diploid genotypes with 2*n* = 2 *x* = 32 chromosomes; tetraploid 2*n* = 4 *x* = 64 chromosomes, and triploid 2*n* = 3 *x* = 48 chromosomes [9,10]. *M. officinalis* is a perennial shrubby plant, with a height of 30–150 cm with fluffy hairs surrounding all parts [8,11]. The stem is erect, branched, usually glabrous, and quadrangular. The leaves are in decussate pairs, petiolate, soft, ovate, 2–8 cm long, 3 cm broad, the upper cuneate, the lower cordate at base, crenate-toothed, subglabrous, sometimes with glandular hairs or punctuate glands beneath. The leaf surface is gross and deeply streaked, and the leaf edge is scalloped or toothed [6,8]. Flowers are commonly white or pale pink with small clusters of 4 to 12 blossoms in the summer. They have a peculiar lemon-like flavor and fragrance [6,8]. The subspecies of *M. officinalis* can be differentiated through the shape of calyx and the density of different types of hairs. The middle tooth of the three upper lip teeth of the fruiting calyx is approximately three-sided for ssp. *officinalis* while it is decent, shorted, or emarginated for ssp. *altissima* [9].

*M. officinalis* is a cross-pollinating species and has complete flowers with petals. Two stamens and four-lobed ovaries can give rise to 1–4 nutlets. The seeds are very small about 1–1.5 mm long, with ovate dark brown or black color. The weight of seeds is 0.5 to 0.7 g and they can be considered fragile as a long storage period (5 years) can induce a decrease in germination vigor [6,8]. The plant possesses a highly branched root system, which guarantees the plant excellent adaptive capabilities; the upper parts of the plant perish at the beginning of the winter, while in spring new saplings re-emerge from the roots [7]. *M. officinalis* is cultivated all over the world, with the Mediterranean basin or Western Asia are considered as the area of origin [9]. There is a different opinion that suggests this plant is originated from a more wide area comprising South and Central Europe, Northern Africa, the Caucasus, and Northern Iran [11,12]. *M. officinalis* occurs naturally in sandy and loamy fertile soils but sometimes can grow on moist wasteland from sea level to the mountains [5,8,12]. The plant prefers well-drained soils with a pH range from 5 to 7, it can grow in full sun, but also partial shade. When the plant grows in semi-shade, it produces bigger leaves compared to the sunny situation. This means that *M. officinalis* can promptly develop in a temperate environment (15 to 35 °C) necessitating at least 500 to 600 mm precipitation during all growing seasons. It suffers from drought, particularly in the establishment year, however after the root system is developed, requires a reduced amount of water [8]. The plant can be considered for easy cultivation and this reason can be suggested for beginners. In addition, given its adaptive capacities and strength, some gardeners consider it a weed [5].

3. Biochemical Compounds of *Melissa officinalis*

*M. officinalis* is widely used in food, medicine, and cosmetics. Its application is particularly related to the presence of valuable phytochemicals such as pleasant volatile compounds (e.g., Neral, geranial, citronellal), phenolic acids (e.g., rosmarinic acid), flavonoids (e.g., luteolin) and many others (Fig. 1). In 1998, Carnat and co-authors have
reported that *M. officinalis* leaves contained 0.32% essential oil, 11.8% polyphenol compounds (hydroxycinnamic compounds 11.3%, RA 4.1%, and total flavonoid compounds 0.5%) [13]. Later, Shakeri and co-workers described that *M. officinalis* contained volatile compounds, triterpenoids, phenolic acids, and flavonoids [6].

### 3.1 Volatile Oils

The volatile compounds of *M. officinalis* have been intensively studied in many countries. The chemical composition of volatile oils of *M. officinalis* from different origins is represented in Table 1 (Ref. [2,14–25]). According to the literature reports, the major components of the *M. officinalis* essential oils are mono-, sesquiterpenes, and aliphatic aldehydes, alcohols such as geranial, neral, and citronellal, geranyl acetate, (E)-caryophyllene, caryophyllene oxide, geraniol, pinene, sabinene, thymol, carvacrol and muurolene, decadienal and trans-carveol [2,6,13–25]. The numerical cluster analysis has been carried out based on 15 major essential oil components from thirty *M. officinalis* samples published in the literature. Geranial/neral (I); geraniol/caryophyllene oxide (II); citronellal (III); α-pinene/caryophyllene oxide (IV) chemotypes have been reported for the essential oil compositions of *M. officinalis* [14].

### 3.2 Triterpenes

Several new triterpenes were discovered from *M. officinalis*. Mencherini and others have been isolated six new ursane-type triterpenes from the leaves and leaves of *M. officinalis* [26]. Recently, three new ursene triterpene glycosides (melissiosides A–C) with promising antimicrobial actions have been isolated from the aerial parts of *M. officinalis* [27]. In 2015, Ji and co-authors isolated serrata-genic acid, 2α,3β-dihydroxy-urs-12-en-28-oic acid, ursolic acid, oleanolic acid, 2α,3β,29-tetrahydroxyolean-12-en-28-oic acid from *M. officinalis* leaves [28]. Ursolic and oleanolic acids were also detected in the methanol extract from dried aerial parts of lemon balm [29].

### 3.3 Phenolic Compounds

Hanganu and co-authors (2008) have reported that *M. officinalis* leaves contain 0.64% flavonoids expressed in rutinoside and 8.962% phenyl-propane derivatives expressed in caffeic acid [30]. Six polyphenolic compounds, i.e., caftaric acid, caffeic acid, p-cumaric acid, ferulic acid, luteolin, and apigenin were identified from ethyl-ether, ethyl acetate, and 1-buthanol extracts of *M. officinalis* leaves [30]. Toth and co-authors have reported that an important phenolic active compound of *M. officinalis* was RA [31]. In 2002, Patora and Klimek isolated for the first time a new glycoside compound, 7-O-beta-D-glucopyranoside-3'-O-beta-D-glucuronopyranoside from the leaves of *M. officinalis* [32]. In 2015, Ji and co-authors isolated thirteen compounds, including protocatechuyl aldehyde, vanillin, luteolin, rosmaricin acid, luteolin-7-O-beta-D-glucopyranoside from the *M. officinalis* leaves [28]. Luteolin, luteolin 7-O-beta-D-glucopyranoside, apigenin 7-O-beta-D-glucopyranoside, luteolin 7-O-beta-D-glucuronopyranoside, luteolin 3'O-beta-D-glucuronopyranoside and luteolin 7-O-beta-D-glucopyranoside-3'-O-beta-D-glucuronopyranoside have been isolated from the leaves of *M. officinalis* [32].

### 3.4 Others Compounds

β-Sitosterol and palmitic acid were isolated from the leaves of *M. officinalis* [28]. Aqueous *M. officinalis* preparations were rich in total phenols (2.9–7.8 mg/mL) and the examined macroelements, 4.4–11.6, 12.2–1152, and 200–
Table 1. Volatile compounds of *M. officinalis*.

<table>
<thead>
<tr>
<th>Origin</th>
<th>Plant’s part</th>
<th>Composition</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Algeria</td>
<td>leaves</td>
<td>geranial (44.20%), neral (30.20%) and citronellal (6.30%)</td>
<td>[15]</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>aerial parts</td>
<td>citronellal (18.5%), geraniol (15.2%), citronellol (9.5%), geranly acetate (7.2%) and geranial (5.9%)</td>
<td>[16]</td>
</tr>
<tr>
<td>Egypt</td>
<td>aerial parts</td>
<td>geranial and neral (54.82%)</td>
<td>[17]</td>
</tr>
<tr>
<td>Greece</td>
<td>leaves</td>
<td>β-pinene (6.4–18.2%), sabine (6.9–17.4%), (E)-caryophyllene (7.2–15.3%), caryophyllene oxide (12.6–24.4%)</td>
<td>[18]</td>
</tr>
<tr>
<td>Iran</td>
<td>flowers</td>
<td>trans-carveol (28.89%), citronellol (25.24%), δ-3-carene (5.26%), citronellol (4.9%), geraniol (2.2%), 1-octene-3-ol (2.03%) and spathulenol (2.06%)</td>
<td>[19]</td>
</tr>
<tr>
<td>Iran</td>
<td>aerial parts</td>
<td>geranylacetate (27.9%), citral (24.2%), citronellol (8.4%), and citronellol (7.6%)</td>
<td>[2]</td>
</tr>
<tr>
<td>Iran</td>
<td>leaves</td>
<td>before flowering stage: decadienal (29.38%), geraniol (25.3%), caryophyllene oxide (8.75%), geranyl acetate (5.41%); in the flowering stage: decadienal (28.04%), geraniol (24.97%), caryophyllene oxide (7.55%), caryophyllene E (4.65%), and after flowering stage: carvacrol (37.62%), methyl citronellate (32.34%), geranyl acetate (5.82%), caryophyllene (5.50%)</td>
<td>[20]</td>
</tr>
<tr>
<td>Jordan</td>
<td>leaves</td>
<td>caryophyllene oxide (43.6%), muurolene (28.8%)</td>
<td>[21]</td>
</tr>
<tr>
<td>Poland</td>
<td>aerial parts</td>
<td>camphene, citronellal, neral, methyl citronellate, geranial, α-copaene, β-caryophyllene, humulene, caryophyllene oxide</td>
<td>[22]</td>
</tr>
<tr>
<td>Romania</td>
<td>aerial parts</td>
<td>citral (neral and geranial) (16.10%), citronellal (3.76%) and trans-caryophyllene (3.57%)</td>
<td>[23]</td>
</tr>
<tr>
<td>Russia</td>
<td>aerial parts</td>
<td>citronellol (36.71%), geraniol (27.20%)</td>
<td>[24]</td>
</tr>
<tr>
<td>Tajikistan</td>
<td>aerial parts</td>
<td>geranial (43.2%), neral (31.5%), (E)-anethole (12.3%), (E)-caryophyllene (4.0%) and citronellal (2.8%)</td>
<td>[14]</td>
</tr>
<tr>
<td>Turkey</td>
<td>aerial parts</td>
<td>citronellal (36.62–43.78%), citral (10.10–17.43%), thymol (0.40–11.94%), and β-caryophyllene (5.91–7.27%)</td>
<td>[25]</td>
</tr>
</tbody>
</table>

Fig. 2. Various health properties of the *Melissa officinalis*.

740 μg/mL for Na, K, and Ca, respectively [33]. In summary, *M. officinalis* represents a promising source of phytochemicals that can contribute to the beneficial properties of the plant.

### 4. Health Properties of *Melissa officinalis*

The *Melissa officinalis* possess diverse biological and health properties such as anxiolytic, antioxidant, antidepressant, anticancer, antinociceptive, anti-epileptic, anti-angiogenesis, antimicrobial, anti-inflammatory, hypolipidemic, and hypoglycemic. Various health properties of the *Melissa officinalis* are depicted in Fig. 2.

#### 4.1 Antiviral Activity

COVID-19 has been defined as a pandemic on 11 March 2020 and entered the fifth position of the most important and documented pandemics since the 1918 influenza outbreak [34]. Worldwide researchers and clini-
cians hardly worked to find effective therapies and develop vaccines to reduce and prevent infectivity. Plants’ bioactive compounds represent a major field of research for the development of safe and effective treatments potentially useful to fight against COVID-19. Several studies showed that *M. officinalis* possessed antiviral activity against a wide number of viruses (Fig. 3) [35]. Today’s research aims to recognize its antiviral bioactive compounds against the main protease and spike protein of COVID-19. Docking experiments conducted by Prasanth and his colleagues showed that three phytoconstituents from *M. officinalis*, namely, luteolin-7-glucoside-3′-glucuronide, melitric acid-A, and quadranoside-III, possessed a greater binding affinity and stability towards the primary protease and spike protein of COVID-19 [36]. Similar results were previously published by Elekofehinti *et al.* [37] who found that melitric acid A and salvanolic acid A had higher affinity to the main protease of coronavirus COVID-19 than lopinavir and ivermectin using both AutodockVina and XP docking algorithms.

Influenza viruses that belong to a virus family known as Orthomyxoviridae are also a target of the active ingredients of *M. officinalis*. The H9N2 subtype virus, a member of the influenza family that has been classified as a low pathogenic virus, had unfortunately developed viral resistance to all the conventional drugs approved by the Food and Drug Administration (FDA) [38,39]. Recent findings showed that *M. officinalis* essential oil (monoterpenaldehydes citral a, citral b) could inhibit influenza virus replication by different mechanisms of action such as masking the host cellular surface protein, intracellular steps, and direct virucidal effect by structural damage [40]. It was also demonstrated that the combination of *M. officinalis* essential oil with oseltamivir augmented the inhibitory effect of the antiviral drug particularly at very low concentration (0.005 mg/mL) [40]. Similar results on the effect of the hydroalcoholic extract of *M. officinalis* on the growth of influenza virus subtype H1N1 in the MDCK cell culture were demonstrated by Jalali *et al.* [41].

Antiviral activity of extracts from *M. officinalis* has also been described for herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) [42,43]. Astani *et al.* [44] evaluated the antiviral activity of *M. officinalis* extract by choosing active phenolic compounds against HSV-1 and investigating their mechanism of action. They found that both the aqueous *M. officinalis* extract and the phenolic molecules significantly decreased the infectivity of HSV-1 at the early stage of virus replication. This action was mainly due to the inhibition of herpes viral attachment caused by the predominant phenolic compound in *M. officinalis* extract RA at a concentration of 9.75 µg/mL [44]. The plant extract revealed superior virucidal activity if compared to single compounds, probably imputable to multiple interactions of phytochemicals [45]. The hydroalcoholic extract of *M. of-
M. officinalis rich with RA (4.1% w/w) decreased the cytopathic effect of HSV-2 on Vero cells (ATCC CCL-81) at concentrations starting from 25 μg/mL with a maximum inhibiting effect (60%) obtained at a concentration of 0.5 mg/mL [21]. Allahverdiyev et al. [46] proved that the volatile oils obtained from M. officinalis at concentrations above 100 μg/mL reduced the proliferation of HSV-2. They suggested that this activity could be due to the citral and citronellal that characterizes the plant’s volatile oil by inhibiting protein synthesis in virus cells [46].

Worldwide HIV in 2019 affected approximately 38 million people, mainly adults (36.2 million) and 1.8 million children (<15 years old) [47]. Advances in HIV pharmacotherapy produced the current antiretroviral therapy (HAART), which significantly contributed to prolonging survival and alleviating patients’ suffering [47]. Nonetheless, side effects and drug resistance are two key factors to consider for the development of new antiviral to be potentially added to the current regimen. Geuenich et al. [48] proved that aqueous extracts from M. officinalis exhibited high and concentration-dependent activity against HIV-1 virions due to the augmentation of the virion’s density before its surface engagement.

Enterovirus 71 (EV71) is one of the major pathogens causing Hand, foot, and mouth disease (HFMD) in infants and children aged under 5 [49]. A small proportion of EV71-infected patients develop severe complications that can lead to death which urge the progress toward novel drugs affecting patients’ medical history [50]. It has been reported that M. officinalis extract (due to its high RA content) could block plaque formation and viral protein synthesis in EV71-infected cells, suggesting a cytopathic effect of this methanolic extract [51].

4.2 Antibacterial Activity

Generally, aromatic plants are rich in essential oils with significant antimicrobial properties. GC-MS analysis revealed that the chemical composition of the essential oils extracted from M. officinalis was citronellal (37.33%), thymol (11.96%), citral (10.10%), and β-caryophyllene (7.27%). According to the disk diffusion agar assay and micro-dilution method, strong antimicrobial effects of the oils against Salmonella typhimurium, Escherichia coli, Listeria monocytogenes, and Staphylococcus aureus were found [51]. Results also showed that S. aureus was the most sensitive bacteria with the lowest MIC value (0.12 mg/mL) [51].

E. coli ATCC 25922 and the multiresistant strain of Shigella sonnei IPH-MR exhibited high sensitivity to the essential oil of M. officinalis [52]. The petroleum ether extract of M. officinalis demonstrated varying inhibitory potencies against Gram-positive bacteria in particular Staphylococcus aureus and Pseudomonas aeruginosa with MICs ranging between 1.65 and 191.40 μg/mL, while no antibacterial effect was reported against Escherichia coli and Klebsiella pneumonia [53]. Similar results were recorded for the hydro-alcoholic extract of M. officinalis which showed interesting antibacterial activity against S. aureus and Staphylococcus epidermidis, while gram-negative bacteria such as E. coli were less involved [54].

Notably, essential oils revealed significant antifungal activity, even if not in all cases. Prominent was the low MIC and MFC of the essential oil of M. officinalis against Trichophyton tonsurans if compared to the reference drug bifonazole (antimycotic) [52]. Also, the crude petroleum ether extract and its derived fractions demonstrated remarkable antifungal activities against Candida albicans, Candida krusei, and Candida glabrata with MICs of 0.30–345.10 μg/mL [53].

4.3 Anti-inflammatory Effects

The anti-inflammatory activities of M. officinalis leaves were widely examined. Results showed that its essential oil possessed anti-inflammatory activities, supporting its traditional use in different diseases related to inflammation and pain [55]. Recent works proved that the extract of M. officinalis exerted anti-inflammatory and antinociceptive effects by interacting with muscarinic and nicotinic receptors and the L-arginine-nitric oxide pathway which were ascribable to RA, terpenoids, and flavonoids [56]. RA and flavonoids are known to block different enzymes involved in the inflammatory process, such as cyclooxygenase, lipooxygenase, and monoxygenase [57].

Due to these anti-inflammatory properties, the extract of M. officinalis proved to have good effects in relieving symptoms of atopic dermatitis [57]. The anti-inflammatory property of M. officinalis is depicted in Fig. 4. Ramanauskin et al. [58] investigated the effect of M. officinalis extract and its RA content on skin cells in normal conditions and under oxidative stress. The work on human keratinocyte cells showed that, in oxidative stress conditions, RA decreased intracellular ROS by about 28%, while enhancing cell viability by 10–24% (at a concentration of 0.25–0.5 mg/mL) and protecting cells from H2O2 damage [58].

Anti-inflammatory and antinociceptive effects of M. officinalis were investigated with the histamine- and carrageenan-induced paw edema tests in rats and mice. It was found that pretreatment with the aqueous extract of M. officinalis considerably lessened inflammmagen-induced paw edema in rats and diminished the nociceptive response in mice [59].

Müzell and his colleagues assessed the anti-inflammatory activity of an aqueous extract of M. officinalis in hepatic and renal lesions caused by acetaminophen in animal models [60]. Even if not hepatoprotective, the extract demonstrated a nephroprotective activity against acetaminophen lesions and exhibited an anti-inflammatory effect on carrageenan-induced pleurisy [60].
Fig. 4. Anti-inflammatory property and neuroprotective effects of *Melissa officinalis* L.

*M. officinalis* was also found to be a good source of chemopreventive agents. Its extracts demonstrated cytotoxicity in breast cancer cells (MDAMB-231) even at low concentrations (100 µg/mL), with also a pronounced impact on cell migration and proliferation, while resulting in poorly toxic for HaCat cells (500 and 1000 µg/mL). Differently, stem extracts resulted highly cytotoxic (>100 µg/mL) [61].

### 4.4 Neuroprotective Properties

The number of people suffering from neurological disorders such as neurodegenerative diseases as well as psychiatric ones has lately increased worldwide [62]. *M. officinalis* has traditionally been used for its impact on the nervous system owing to elevated contents of phenolic compounds and tocopherols [52]. Both crude ethanol extract of *M. officinalis* and its fractions blocked acetylcholinesterase *in vitro* and *in vivo* [63–65]. Similarly, methanol and aqueous extracts of *M. officinalis* possessed a significant protective effect on hydrogen peroxide-induced toxicity in PC12 cells mainly due to monoamine oxidase inhibition [66]. In addition, the effects of an ethanol extract of *M. officinalis* were tested in the hippocampus of pilocarpine treated rats, as a potential model of epilepsy [67]. In particular, the antioxidant and anti-inflammatory activity of the extract orally administered at 250 mg/kg impacted positively on Nrf2/ARE-1 signaling pathway, Na+/K+-ATPase activity, and GABA while glutamate and acetylcholine diminished and reduced neuronal loss, adding a new potential beneficial effect (anti-epileptic) of *M. officinalis* to its wide uses.

Hassanzadeh *et al*. [68] reported that aqueous extract of *M. officinalis* could support neuroprotective effects against ecstasy-induced neurotoxicity in hippocampal primary culture. In addition, Yoo and his colleagues proved that oral administration of *M. officinalis* could augment differentiation and cell growth by lessening serum corticosterone while boosting GABA levels in the mouse dentate gyrus [69].

The effect of *M. officinalis* on hypoxia-induced neuronal death in a cortical neuronal culture system was tested both *in vitro* and in transient hippocampal ischemia *in vivo* models [70]. Cytotoxicity assays showed significant protection of *M. officinalis* against hypoxia in cultured neurons by decreasing caspase3 activity and TUNEL-positive cells significantly. *M. officinalis* oil was found to inhibit malondialdehyde levels and attenuate the decrease of the antioxidant capacity in the hippocampus. Pro-inflammatory cytokines TNF-α, IL-1β, and HIF-1α mRNA levels and HIF-1α gene expression were highly decreased by the treatment with the plant [70]. Rosmarinic acid, the predominant compound of *M. officinalis*, demonstrated a cytotoxic effect on rat glioblastoma C6 cells by suppressing cell proliferation and inducing cell death through necrosis [71]. Extracts prepared with 70% ethanol were the most active on glioblastoma cells by initiating the generation of intracellular ROS and by inducing apoptosis and necrosis [71]. The pathophysiology of spinal cord injury (SCI) has a typically poor prognosis, that could lead to severe disabilities due to motor, sensory, and autonomic nervous system damage.
Fig. 5. Cardio-protective effects induced by *Melissa officinalis* L. [78].

[72]. In a study conducted on adult male rats, Hosseini et al. [73] showed that human umbilical cord blood stem cells in combination with *M. officinalis* had neuroprotective effects in the SCI model. Researchers examined the behavioral mechanism of action of *M. officinalis* extracts on scopolamine-induced memory impairment in rats [64,74]. Although some studies showed that *M. officinalis* extract was completely inactive [74]; *M. officinalis* extract considerably improved scopolamine-induced learning deficit by enhancing the learning and memory of rats in other studies [64,74]. Results proved that *M. officinalis* extract reduced AChE mRNA level by 52% in the frontal cortex with a concomitant noteworthy blockade of BACE1 mRNA transcription [75]. More recently, *M. officinalis* oil 1 µg/mL was studied in isolated mouse ileum and atria tissues as a model of anxiety-related disorders [76]. The work reported that the oil could stop both spontaneous and induced ileum contractions, however, it reduced only slightly AChE activity, suggesting as other mechanisms (voltage-gated Ca²⁺ channels or muscarinic receptors) could be involved in *M. officinalis* effects.

5. Human Clinical Trials

*M. officinalis* extracts have been proved in clinical trials focused on a variety of diseases, mainly related to neurological disorders, i.e., anxiety and sleeping difficulties, but also metabolic problems and infantile colic. *M. officinalis* has been used as a cure for memory, cognition, anxiety, depression, and heart palpitations for many centuries. Preclinical animal studies on this plant confirmed its evocative cardiovascular effects including anti arrhythmogenic, negative chronotropic and dromotropic, hypotensive, vasorelaxant, and infarct size–reducing, by the use of different extracts (aqueous, alcoholic, and hydroalcoholic), essential oil, or isolated compounds. Nonetheless, only the effectiveness of *M. officinalis* on heart palpitations has been verified in humans. Antioxidant free radical–scavenging properties, oxidative stress modulation, anti-inflammatory effects, activation of M2 receptors and antagonism of β1 receptors in the heart, blockage of voltage-dependent Ca²⁺ channels, stimulation of endothelial nitric oxide synthesis, and prevention of fibrotic disease are the biological and biomolecular mechanisms suggested for the cardiovascular effects of *M. officinalis*. Furthermore, the principal active element of *M. officinalis* called rosmarinic acid has been demonstrated to have significant cardiovascular effects [7]. More recently, the same research group published a novel work on myocarditis using a rat model, suggesting the protective effects of this plant on cardiac function and related oxidative stress [77]. The cardio-protective effects induced by *M. officinalis* are depicted in Fig. 5 (Ref. [78]).

For the neurological effects, some authors investigated in the UK addressed the improvement of memory and brain function in healthy people by applying a combination of *Salvia officinalis* L., *Rosmarinus officinalis* L., and *M. officinalis* (SRM) [79]. The work showed that an
oral administration of *M. officinalis* combination at a dose of 5 mL twice a day for 2 weeks was more effective compared to placebo. Araj-Khodaei *et al.* [80] with a study on neurological disorders used *M. officinalis* to treat 45 adult outpatients who met the diagnosis (Diagnostic and Statistical Manual of Mental Disorders) for major depression, and were randomly assigned to 3 groups to daily receive either 2 g of *M. officinalis* or 2 g of *Lavandula angustifolia* Mill. or also fluoxetine (20 mg) and were assessed until 8 weeks [80]. Although the results were promising (usefulness of the extracts in moderate depression), the absence of a placebo group was relevant for the conclusion of the study, suggesting that more work is necessary to support the use of these plants to treat depression.

Other authors, researched neurological disorders [81]. An *M. officinalis* extract enriched in RA was tested in a randomized placebo-controlled double-blind 24-week trial by evaluating the safety and tolerability (primary endpoint) of RA (500 mg daily) and its clinical effects and disease-related biomarker changes (secondary endpoints). The group of patients (n = 23) was affected by mild dementia as a result of Alzheimer’s disease (AD). The outcomes demonstrated that no difference in vital signs or physical and neurologic examination was perceived between the placebo and *M. officinalis* groups. In addition, no severe adverse effects were found while the cognitive function was not modified in both groups. The authors concluded that *M. officinalis* extract (500 mg of RA taken daily) was safe and well-tolerated for AD patients. Therefore, these data suggested that RA can impact AD neuropsychiatric symptoms and can stop the deterioration of AD patients’ conditions. Even though these investigations have been recent, it should be noted that several studies on the effect of *M. officinalis* to treat neurological disorders were reported more than a decade ago. Burns *et al.* [82] carried out a randomized, double-blind, placebo-controlled trial to study the effect of *M. officinalis* oil against agitation in AD. However, aromatherapy with *M. officinalis* oil was not effective. Also, years before, Kennedy *et al.* [83] conducted a similar study. In this case, the authors analyzed the effects of *M. officinalis* on the modulation of mood and cognitive performance [83]. High doses of *M. officinalis* (1600 mg) could improve cognitive performance. Other researchers conducted a similar study focusing on the efficacy and safety of *M. officinalis* extract in mild to moderate AD patients [84]. The use of 60 drops per day demonstrated an improvement in cognitive function after 4 months of treatment.

Other researchers have reported that *M. officinalis* could impact anxiety or sleep disorders. Indeed *M. officinalis* leaves (*Melissa capsule*) were evaluated on anxiety and sleep quality in patients undergoing coronary artery bypass surgery [85]. Eighty patients were administered three times a day with an herbal drug (500 mg of *M. officinalis* leaves) or a placebo (500 mg of wheat starch). Forty-nine % of the patients reduced their anxiety levels at seven days and 54% improved their sleep quality [85]. Other authors showed that *M. officinalis* essential oil was effective in reducing agitated behavior in the elderly affected or not by dementia [86]. The study was conducted in a nursing home recruiting 39 patients affected by dementia and 10 control patients (no dementia). Treatment was given for two weeks followed by a two-week washout period before starting subsequent treatment. The results of the study suggested that *M. officinalis* essential oil could effectively decrease anxiety, however in patients without dementia.

Tavares-Silva and collaborators proved the usefulness of *M. officinalis* and *Phytolacca americana* L. (syn. *Phytolacca decandra* L.) alone or in combination, in children affected by sleep bruxism [87]. Fifty-two children participated in this trial, where *M. officinalis* reduced sleep bruxism up to 30 days after treatment. Another research group also discovered the combination of *M. officinalis* and *Nepeta menthoides* Boiss. & Buhse in sleep disorder [88]. The trial evaluated 80 patients treated with the 1000 mg dose of *M. officinalis* plus 400 mg of *N. menthoides* or a placebo for four weeks. The study established that a combined regimen possessed a substantial activity against insomnia.

In other studies carried out in Iran and UK through randomized, double-blind, placebo-controlled trials, high response to the use of *M. officinalis* to treat anxiety was observed. In the study conducted by Alijaniha *et al.* [89] *M. officinalis* extract was tested against heart palpitation. Leaf extract of *M. officinalis* (500 mg two times per day up to 14 days) considerably lessened the incidence of anxiety and palpitation, while no side effect was reported. Similarly, in the UK, two studies were carried out on the use of *M. officinalis* for anxiety problems. In the first one, the effects of *M. officinalis* on laboratory-induced psychological stress were examined using a 600 mg dose of herbal extract. This dose decreased the negative mood effects of the defined intensity stressor simulation while augmenting the self-ratings of calmness [90]. In the other work, the anxiolytic effect of the herbal combination was assessed during laboratory-induced stress [91]. In this case doses of 80 mg of *M. officinalis* and 120 mg of *Valeriana officinalis* L. improved the negative effects of the defined intensity stressor simulation on ratings of anxiety. It is worth noting that another study tested the effects of “cyracos” (standardized extract of *M. officinalis*) in anxiety disorders and sleep disturbance [92]. Long-lasting administration of this extract cyraco (600 mg per day up to 15 days) diminished the stress-related effects, such as insomnia (42%), anxiety (18%), and anxiety-associated symptoms (15%).

However, the use of *M. officinalis* has not only been studied for neurological disorders or patients suffering from anxiety and stress. Some other studies were redirected to other problems. Darvish-Mofrad-Kashani and collaborators studied the response of *M. officinalis* in behavior modifications [93]. In this work, the efficacy and safety of *M.
Matricariae recutita

M. officinalis

demonstrated the effectiveness of M. officinalis in improving hypoactive sexual desire disorder in 89 women were evaluated. The treatment doses were 500 mg per day of aqueous extract of M. officinalis or placebo. Results demonstrated that M. officinalis extract at 4 weeks significantly increased desire, arousal, lubrication, orgasm, satisfaction, and pain scores compared to placebo in hypoactive sexual desire disorder in women. Other investigations were conducted on the use of M. officinalis by diabetic patients or for the treatment of metabolic disorders. Nayebi et al. [94] described the potential effect of M. officinalis in diabetic patients (type 2). The work analyzed 37 dyslipidemic diabetic patients treated or not with 500 mg capsules per day for up to 3 months. M. officinalis could significantly reduce only serum triglyceride level, while no other metabolic alteration was noted if compared to the control group. Another group of researchers also tested the hydroalcoholic extract of M. officinalis in type 2 diabetic patients. The clinical trial was conducted with 62 patients treated with M. officinalis or placebo of 700 mg per day twice for 12 weeks. M. officinalis caused a substantial modulation in fasting blood sugar, glycated hemoglobin (HbA1c), and systolic blood pressure [95]. On the same line, M. officinalis was suggested to modify biomarkers of oxidative stress, inflammation, and lipid profile in patients with stable chronic angina [96]. Indeed, 80 patients participated in this clinical trial and were challenged with a dose of 3 g per day for 8 weeks. M. officinalis capsules significantly ameliorated the lipid profile, malondialdehyde (MDA), highly sensitive c-reactive protein (hs-CRP) and PNO1 in patients with stable chronic angina. More recently, M. officinalis was studied in systolic and diastolic blood pressures of 49 hypertensive patients, receiving 400 mg/d capsules of the extract for 4 weeks [97]. The plant was able to significantly reduce blood pressure (systolic and diastolic) up to the follow-up period of 10 weeks in this double-blind, controlled, randomized crossover study. Furthermore, a randomized, double-blind, placebo-controlled trial with supplementation of M. officinalis evaluated borderline hyperlipidemia patients [98]. Herbal capsules of M. officinalis exhibited interesting results in hyperlipidemic patients, reducing low-density lipoprotein (LDL) and aspartate transaminase (AST) in patients treated with 500 mg of M. officinalis.

Finally, we must highlight the studies carried out with this plant to treat infantile colic. Martinelli et al. [99] demonstrated the effectiveness of Matricaria chamomilla L., M. officinalis, and Lactobacillus acidophilus tyndallized (HA122) in infantile colic. The children (n = 176) were treated for up to 28 days. Crying time was significantly shorter in the group that received M. chamomilla, M. officinalis, and L. acidophilus tyndallized than the group that received only Lactobacillus reuteri or simethicone. Similar to the previous work, another study investigated the effectiveness and side effects of M. officinalis associated or not with Matricariae recutita and Foeniculum vulgare in infantile colic during one-week treatment. Again crying time was lessened in 85.4% of subjects compared to control (48.9%) while no side effects were reported [100].

The use of M. officinalis for various diseases, from neurological, metabolic disorders to infantile colic opens a new insight into scientifically supported treatments.

6. Toxicity

As for numerous plants, also M. officinalis can exert toxicity if not optimally used.

6.1 Cell-based Toxicity

An aqueous extract of M. officinalis exhibits showed low toxicity on RC-37 cells a cultured line derived from African green monkey kidneys, with a 50% cytotoxic concentration of 350 µg/mL and a maximum non-cytotoxic concentration of 150 µg/mL [101] and inhibited the proliferation of the NCI-H460 cells, with a growth inhibition 50% (GI50) concentration of 200 µg/mL [102]. M. officinalis hydroethanolic extract showed a cell viability of 13% at 1000 µg/mL after 72 h on Human Colon Cancer Cell Line (HCT-116) [103] while its ethanolic inhibited the proliferation of the NCI-H460 cells, with a GI50 concentration of 100.9 µg/mL [102]. M. officinalis decoctions and hot extract showed an antiproliferative effect on human tumor cell lines, with GI50 ranging from 51 to 258 µg/mL for breast (MCF-7), non-small lung (NCI-H460), cervical (HeLa), and hepatocellular carcinoma (HepG2) [104] and at a concentration of 500–1000 µg/mL for human colon cancer cell lines DLD-1 HCT116, SW620, HT-29, and inhibited HT-29 cells [105]. M. officinalis decoctions also showed hepatotoxicity activity with GI50 greater than 400 µg/mL on fresh porcine liver cells, PLP2 [106]. M. officinalis volatile oil was non-toxic to Hep-2 cells, a human cervical carcinoma cell line at 100 µg/mL [46] but induced a neurotoxicity effect on mixed cortical cell cultures from 16- to 18-day-old rat embryos (Sprague-Dawley strain) at the same concentration via volt aggregated sodium channels [106].

6.2 Animal-based Toxicity

M. officinalis leaves essential oil extract showed no acute toxicity in rats treated with 2000 mg/kg [30]. The oral administration of aerial parts essential oil of M. officinalis presents the oral LD50 in BALB/c mice (2.57 g/kg). This oil altered animal behavior and liver and kidney biochemical parameters at doses higher than 1 g/kg in BALB/c mice. Besides, an increased rate of lipid peroxidation and a depletion of antioxidant capacity of the liver and kidney suggest moderate toxicity [107]. M. officinalis whole methanolic and aqueous extracts were found to be safe or non-toxic to rats up to 2000 (mg/kg b.w.) with no mortality in Swiss albino mice [108]. This suggests that the organic extracts of M. officinalis are less toxic through the oral route than the essential oil extracts irrespective of the plant parts. In
addition, *M. officinalis* aqueous extract showed to cause genotoxic and histopathologic damage to the liver, kidneys, heart, and spleen if consumed by *Oncorhynchus mykiss* fish at doses greater than 450 mg/kg [109], while ethanolic extract showed no antigenotoxic/antimutagenic properties in Swiss albino mice at 100–250 mg/kg [110]. However, the European Commission, the Panel on Additives and Products or Substances used in Animal Feed could not conclude on the safety of the use of a dried aqueous ethanol extract of *M. officinalis* leaves as a sensory feed additive for all animal species [111]. On the other hand, a randomized controlled trial using a single dose of *M. officinalis* extract comprising 500 mg rosmarinic acid, showed to be harmless and well tolerable in healthy humans [112]. This is confirmed by randomized clinical trials where different treatment regimens of *M. officinalis* extracts also showed no adverse effects in humans [84,94,95,112]. Overall, though *M. officinalis* toxicity data are scarce and have been poorly investigated despite the variety of practical applications in medical science, available data point out its putative safety in human beings.

7. Conclusions and Future Perspectives

*M. officinalis* is a medicinal plant with numerous health properties and is a curative tool for fighting cardiovascular, neurological, and psychological disorders. Nonetheless, *M. officinalis* is commonly known and prevalently used for anti-anxiety and anti-depression properties, particularly in the acute setting (among the general population *M. officinalis* is used to calm and relax). As reported in this work, this plant can be useful also in other human conditions, such as palpitation, hypertension, dementia, infantile colic, bruxism, metabolic problems, Alzheimer’s disease, and sexual disorders. Even if the therapeutic effects of *M. officinalis* are well documented and studied, its current use in clinical settings is scarce and anecdotic. Thus this work wants to fill in this gap and suggest clinicians, general practitioners, physiotherapists, and interested people expand the rational use of this recognized curative plant. From a pharmacological point of view, *M. officinalis* possesses a wide number of remarkable properties, i.e., antiviral, anti-inflammatory, antibacterial, neuroprotective among the most common. In particular, antiviral activity is of current interest, because COVID-19 pandemic is still taking its toll and in the future, we will need new therapeutic tools to fight this disease, even in the perspective to co-exist with the SARS-CoV-2 virus. Moreover, given its safety — it is generally well tolerated having no relevant side effects, only occasionally headache, vomiting, abdominal pain, nausea have been reported — *M. officinalis* should be considered in general medicine to increase its use. Medicinal plants should be considered a powerful means to cure human conditions: this review sheds new light on the potential of *M. officinalis* and encourages researchers to increase the therapeutic possibilities of this medicinal plant.

Author Contributions

WZ, CQ, JSR, MDL, MS, MM, FS, PVTF, APM, DC, MK, JTC, RP contributed to the manuscript. WZ, CQ, JSR, MDL, MS, MM, FS, PVTF, APM, DC, MK, JTC, RP collected resources and were responsible for data curation and writing. Literature review analysis was performed by WZ, CQ, JSR, MDL, MS, MM, FS, PVTF, APM, DC, MK, JTC, RP. Reviewing and editing were carried out by JSR and RP. All the authors read and approved the final manuscript.

Ethics Approval and Consent to Participate

Not applicable.

Acknowledgment

Not applicable.

Funding

This research received no external funding.

Conflict of Interest

The authors declare no conflict of interest. JTC is serving as one of the Guest Editor of this journal. We declare that JTC had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to GCA.

References


Dragi̇nic ND, Jakovljevic VL, Jeremic JN, Srejovic IM, Andjic
MM, Rankovic MR, et al. Melissa officinalis L. Supplementa-
tion Provides Cardioprotection in a Rat Model of Experimental
Autoimmune Myocarditis. Oxidative Medicine and Cellular
Longevity. 2022; 2022: 1344946.


MJR, Brooker HJ, et al. A randomised double-blind placebo-
controlled pilot trial of a combined extract of Sage, Rosemary
and Melissa, traditional herbal medicines, on the enhancement
of memory in normal healthy subjects, including influence of

E, Faghizhadze S, et al. A double-blind, randomized pilot study for
comparison of Melissa officinalis L. and Lavandula angusti-
folia Mill. with Fluoxetine for the treatment of depression. BMC
Complementary Medicine and Therapies. 2020; 20: 207.

[81] Noguchi-Shinohara M, Ono K, Hamaguchi T, Nagai T,
Kobayashi S, Komatsu J, et al. Safety and efficacy of Melissa of-
cinalis extract containing rosmarinic acid in the prevention of
Alzheimer’s disease progression. Scientific Reports. 2020; 10:
18627.

et al. A double-blind placebo-controlled randomized trial of
Melissa officinalis oil and donepezil for the treatment of agita-
tion in Alzheimer’s disease. Dementia and Geriatric Cognitive
Disorders. 2011; 31: 158–164.

[83] Kennedy DO, Wake G, Savelev S, Tildesley NTJ, Perry EK,
Wesnes KA, et al. Modulation of Mood and Cognitive Per-
formance Following Acute Administration of Single Doses of
Melissa officinalis (Lemon Balm) with Human CNS Nico-
tinic and Muscarinic Receptor-Binding Properties. Neuropsych-

[84] Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S,
Jamshidi AH, Khani M. Melissa officinalis extract in the treat-
ment of patients with mild to moderate Alzheimer’s disease: a
double blind, randomized, placebo controlled trial. Journal of

MR. Effects of Melissa officinalis on anxiety and sleep quality in
patients undergoing coronary artery bypass surgery: A double-
blind randomized placebo controlled trial. European Journal

[86] Watson K, Hatcher D, Good A. A randomised controlled trial of
Lavender (Lavandula Angustifolia) and Lemon Balm (Melissa Offi-
cinalis) essential oils for the treatment of agitation associated

[87] Tavares-Silva C, Holandino C, Homsani F, Luiz RR, Prodes-
tino J, Farah A, et al. Homeopathic medicine of Melissa offici-
cinalis combined or not with Phytoallca decandra in the treat-
ment of possible sleep bruxism in children: A crossover randomized
triple-blinded controlled clinical trial. Phytomedicine. 2019; 58:
152869.

[88] Ranjbar M, Salehi A, Rezaeizadeh H, Zarshenas MM,
Sadeghniaiat-Haghki H, Mirabzadeh M, et al. Efficacy of a
Combination of Melissa officinalis L. and Nepeta menthoides
Boiss. & Buhse on Insomnia: A Triple-Blind, Randomized
Placebo-Controlled Clinical Trial. The Journal of Alternative and

[89] Alijaniha F, Nasiri M, Afsharypour S, Fallahi F, Noorbala A,
Mosaddeghe M, et al. Heart palpitation relief with Melissa of-
cinalis leaf extract: double blind, randomized, placebo con-
trolled trial of efficacy and safety. Journal of Ethnopharmacol-

[90] Kennedy DO, Little W, Scholey AB. Attenuation of laboratory-
induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosomatic Medicine. 2004; 66:
607–613.

[91] Kennedy DO, Little W, Scholey AB. Anxiolytic effects of a
combination of Melissa officinalis and Valeriana officinalis dur-

[92] Cases J, Ibarra A, Feuillère N, Roller M, Sukkar SG. Pilot trial of
Melissa officinalis leaf extract in the treatment of volunteers
suffering from mild-to-moderate anxiety disorders and sleep dis-

[93] Darvish-Mofrad-Kashani Z, Emaratkar E, Hashem-Dabaghi
(Lemon balm) on Sexual Dysfunction in Women: A Double-
blind, Randomized, Placebo-controlled Study. Iranian Journal of

[94] Nayebi N, Esteghamati A, MeySanie M, Khalili N, Kamalinejad
M, Emitaizy M, et al. The effects of a Melissa officinalis L.-based
product on metabolic parameters in patients with type 2 diabetes
europathy: A randomized double-blinded controlled clinical trial.
Journal of Complementary and Integrative Medicine. 2019; 16:
Asadi A, Shidfar F, Safari M, Hosseini AF, Fallah Husheini H,
Heidari I, et al. Efficacy of Melissa officinalis L. (lemon balm) on
glycemic control and cardiovascular risk factors in individuals with

[95] Javid AZ, Haybar H, Dehghan P, Haghighizadeh MH, Mo-
haghgh SM, Ravanbakhsh M, et al. The effects of Melissa offici-
inalis (lemon balm) in chronic stable angina on serum biomark-
ers of oxidative stress, inflammation and lipid profile. Asia Pa-

[96] Shekariz Z, Shorofii SA, Nabati M, Shabankhani Y, Yousefi SS.
Effect of Melissa officinalis on systolic and diastolic blood pres-
sures in essential hypertension: A double-blind crossover clini-

a promising herbal therapy for patients with borderline
hyperlipidemia-A randomized double-blind placebo-controlled
clinical trial. Complementary Therapies in Medicine. 2016; 26:
136–140.

[98] Martinelli M, Ummarino D, Giugliano FP, Sciorio E, Tortora
C, Bruzzese D, et al. Efficacy of a standardized extract of Ma-
ticariae chamomilla L., Melissa officinalis L. and tannylized
Lactobacillus acidophilus (HA122) in infantile colic: An open
randomized controlled trial. Neurogastroenterology & Motility.
2017; 29.

[99] Savino F, Credi F, Castagno E, Silvestro L, Oggero R. A ran-
domized double-blind placebo-controlled trial of a standardized
extract of Maticariae recutia, Foeniculum vulgare and Melissa of-
cinalis (ColiMil) in the treatment of breastfed colicky infants.

[100] Astani A, Heidary Navid M, Schnitzler P. Attachment and Penetration of Acyclovir-resistant Herpes Simplex Virus II are In-
hibited by Melissa officinalis Extract. Phytotherapy Research.

[101] Magalhães DB, Castro I, Lopes-Rodrigues V, Pereira JM, Bar-
ros L, Ferreira ICFR, et al. Melissa officinalis L. ethanolic ex-
tract inhibits the growth of a lung cancer cell line by interfering
with the cell cycle and inducing apoptosis. Food & Function.

[102] Encalada MA, Hoyo KM, Reheco S, Berasategi I, de Ciriano
MG-I, Ansorena D, et al. Anti-proliferative effect of Melissa of-
cinalis on human colon cancer cell line. Plant Foods for Human


